Home › NDC Lookup › RxCUI directory › RxCUI 2606491

{63 (pirfenidone 267 MG Oral Capsule) } Pack — RxCUI 2606491

RxNorm drug concept · Generic pack
RxCUI 2606491 Generic pack · GPCK ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2606491
Official name{63 (pirfenidone 267 MG Oral Capsule) } Pack
Concept typeGeneric pack (GPCK)
RxNorm statusCurrent RxNorm concept
Also known aspirfenidone 267 MG Capsule 14 Day Titration Pack
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)68 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pirfenidone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats idiopathic pulmonary fibrosis, or IPF, a lung disease where scarring builds up for no known reason. Esbriet and generic pirfenidone capsules and tablets are all labeled f...
  • Take it by mouth three times a day with food, at about the same times each day. You’ll start low and build up over about 14 days. If you miss a dose, don’t double up, and never tak...
  • Nausea, rash, stomach pain, diarrhea, tiredness and decreased appetite are common. Stomach effects are usually worst in the first few months and often ease. Tell us if they get bot...
  • Yes. Pirfenidone can make your skin sensitive to sunlight. Avoid sun and sunlamps, wear sunscreen and cover up daily. Let your doctor know if you develop a rash.
📖 Read our full Pirfenidone guide →

🕸️ Concept Web — How {63 (pirfenidone 267 MG Oral Capsule) } Pack Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {63 (pirfenidone 267 MG Oral Capsule) } Pack RxCUI 2606491

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pirfenidone 1592254
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Esbriet 1592280
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pirfenidone Oral Capsule 1592278
    • Pirfenidone Oral Product 1592276
    • Pirfenidone Pill 1592277
    • Pirfenidone Oral Capsule [Esbriet] 1592282
    • Esbriet Oral Product 1592283
    • Esbriet Pill 1592284
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pirfenidone 267 MG Oral Capsule SCD · 1592279
  • Pirfenidone 267 MG SCDC · 1592275
  • Pirfenidone Oral Capsule SCDF · 1592278
  • Pirfenidone Oral Product SCDG · 1592276
  • Pirfenidone Pill SCDG · 1592277

Brand-Name Concepts

  • Pirfenidone 267 MG Oral Capsule [Esbriet] SBD · 1592285
  • Pirfenidone 267 MG [Esbriet] SBDC · 1592281
  • Pirfenidone Oral Capsule [Esbriet] SBDF · 1592282
  • Esbriet Oral Product SBDG · 1592283
  • Esbriet Pill SBDG · 1592284
  • Esbriet BN · 1592280

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 2606491 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42385-0923-29 270 CAPSULE in 1 BOTTLE (42385-923-29) Pirfenidone Laurus Labs Limited 2022-07-19
42385-0923-54 4 BLISTER PACK in 1 CARTON (42385-923-54) / 63 CAPSULE in 1... Pirfenidone Laurus Labs Limited 2022-07-19
42385-0923-63 2 BLISTER PACK in 1 CARTON (42385-923-63) / 21 BLISTER PACK... Pirfenidone Laurus Labs Limited 2022-07-19
42385-0924-99 3 BOTTLE in 1 CARTON (42385-924-99) / 90 TABLET, FILM COATE... Pirfenidone Laurus Labs Limited 2022-07-19
42385-0925-90 90 TABLET, FILM COATED in 1 BOTTLE (42385-925-90) Pirfenidone Laurus Labs Limited 2022-07-19
42385-0926-90 90 TABLET, FILM COATED in 1 BOTTLE (42385-926-90) Pirfenidone Laurus Labs Limited 2022-07-19
Observed labelers: Laurus Labs Limited (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.